Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MolMed and GSK sign gene therapy deal

This article was originally published in Scrip

Executive Summary

Italy's MolMed has signed a strategic agreement with GlaxoSmithKline to provide gene therapy services to the UK company. The deal is worth €34m over five years in up-front, milestone, service and supply payments. It follows earlier agreements under which MolMed undertook to design the production process and subsequently continue to manufacture GSK's investigational gene therapy for the ultra-rare, life-threatening condition Adenosine Deaminase Deficiency - Severe Combined Immune Deficiency (ADA-SCID). In 2010 GSK formed an alliance with Fondazione Telethon and Fondazione San Raffaele (MolMed was spun out of the San Raffaele Scientific Institute) to address rare diseases using gene therapy carried out on stem cells taken from the patient's bone marrow. The deal focused on ADA-SCID and six further applications of ex vivo stem cell therapy. The current deal specifies that MolMed will supply development, manufacturing and tech transfer services for the clinical application of gene therapies based on viral vector cellular transduction. MolMed chairman and CEO Claudio Bordignon said the agreement "acknowledges the substantial investment the company has made in its development labs and in additional production facilities, ultimately placing MolMed in a leadership position in the global industry."

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028182

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel